None listed
Conditions
Brief summary
This study aims to investigate how quickly two potent anitbiotics used to treat septic patients in the ICU are removed by dialysis. Septic patients often have acute kidney injury and require dialysis support to maintain kidney function. We do not know how well antibiotics are removed by dialysis and therefore do not have appropriate dosing guidelines to ensure adequate therapeutic concentrations of the antibiotic is maintained. This study will measure the changes in antibiotic concentrations over a dialysis session. The results will enable us to more accurately recommend the correct dose and timing for the dose for septic patients with acute kidney injury.
Interventions
Open label pharmacokinetic study of meropenem and tazocin in septic patients requiring slow low efficiency dialysis (SLED) with haemodiafiltration (HDF).
Both the dialysis therapy and antibiotic therapy will be administered regardless of enrolment.
The pharmacokinetic study relates to a single SLED-HDF session, where the antibiotic (meropenem or tazocin) has been administered intravenously prior to the start of the dialysis session. Samples are then taken to measure antibiotic concentrations ov
Open label pharmacokinetic study of meropenem and tazocin in septic patients requiring slow low efficiency dialysis (SLED) with haemodiafiltration (HDF). Both the dialysis therapy and antibiotic therapy will be administered regardless of enrolment. The pharmacokinetic study relates to a single SLED-HDF session, where the antibiotic (meropenem or tazocin) has been administered intravenously prior to the start of the dialysis session. Samples are then taken to measure antibiotic concentrations over time during the dialysis session. Where possble the pharmacokinetic study will be repeated during the next dialysis session which may be 24 or 48 hours later, depending upon the patient's clinicall status.
Sponsors
University of Otago
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Any septic ICU patient, treated with meropenem or tazocin who requires SLED-HDF for the treatment of their acute kidney injury
Exclusion criteria
The next of kin do not consent to particpation. (Rarely will the individual be able to give consent as they will be ventilated and sedated). Intensivist deem the participant is not suitable for the study on clinical grounds.
Outcome results
None listed